Enrolling By Invitation NA INTERVENTIONAL NCT05740111

The PREPAIRD Study: Personalized Surveillance for Early Detection of Pancreatic Cancer in High Risk Individuals (PREPAIRD)

The PREPAIRD Study: Personalized suRveillance for Early Detection and Prevention of Pancreatic cAncer in High Risk inDividuals

Sponsor: Haukeland University Hospital

Conditions Hereditary Pancreatic Cancer

Interventions Annual surveillance

Updated 3 times since 2023 Last updated: Feb 13, 2023 Started: Sep 1, 2022 Primary completion: Dec 31, 2042 Completion: Dec 31, 2042

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Hereditary Pancreatic Cancer, this trial is ongoing. The trial is conducted by Haukeland University Hospital and has accumulated 3 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Enrolling By Invitation NA
Jul 2024 — Sep 2024 [monthly]

Enrolling By Invitation NA
Mar 2023 — Jul 2024 [monthly]

Enrolling By Invitation NA

First recorded

Sep 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Haukeland University Hospital
Helse Sor-Ost
Helse Stavanger HF
Immunovia, Inc.
Oslo University Hospital
St. Olavs Hospital
University Hospital of North Norway
University of Bergen
University of Oslo

Data source: Oslo University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Oslo, Norway